Comparative research on the developmental toxicity of prenatal SSRIs exposure in mice: organ-specific effects and long-term outcomes in offspring

Selective serotonin reuptake inhibitors (SSRIs) are widely used during pregnancy, but whether individual SSRIs differ in their developmental toxicity and long-term effects on offspring remains insufficiently understood. In this study, we comparatively evaluated prenatal exposure to sertraline, fluoxetine, and escitalopram in mice, with particular emphasis on maternal–fetal exposure, organ-specific developmental effects, and persistence of these alterations into adulthood. Pregnant mice received low or high doses of each SSRI from gestational day 0–18. Maternal and fetal biochemical profiles, fetal growth, organ morphology, and developmental markers were assessed, followed by evaluation of corresponding phenotypes in adult offspring. A high-fat diet (HFD) challenge was additionally applied to offspring prenatally exposed to low-dose sertraline to assess susceptibility to later-life metabolic stress. All three SSRIs crossed the placenta and altered maternal–fetal serotonergic homeostasis, but their developmental effects showed clear drug- and organ-specific patterns. The fetal brain exhibited relatively consistent susceptibility across exposure groups, whereas sertraline predominantly disrupted hepatic lipid metabolism and fluoxetine altered developmental markers in the kidney and gonads; escitalopram produced comparatively limited effects. Most fetal alterations in the brain, kidney, and gonads were not accompanied by detectable functional abnormalities at postnatal week 12. In contrast, sertraline-associated hepatic abnormalities, including increased FASN and CD36 expression and lipid accumulation, persisted into adulthood. Prenatal low-dose sertraline exposure also impaired glucose tolerance and insulin sensitivity and exacerbated HFD-induced hepatic lipid accumulation and metabolic injury. These findings demonstrate that developmental toxicity differs substantially among individual SSRIs despite their shared pharmacological class and highlight the importance of drug- and organ-specific evaluation in the long-term safety assessment of prenatal SSRI exposure.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.2005926
Primary Topic
Prenatal Substance Exposure Effects
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative research on the developmental toxicity of prenatal SSRIs exposure in mice: organ-specific effects and long-term outcomes in offspring

Yongguo Dai, Jiawei Zhang, Bin Deng, Xuan Xia et al.
Frontiers in Pharmacology
Prenatal Substance Exposure Effects
article

Comparative research on the developmental toxicity of prenatal SSRIs exposure in mice: organ-specific effects and long-term outcomes in offspring

Yongguo Dai, Jiawei Zhang, Bin Deng, Xuan Xia, Xiaoxiang Sun, Yuxin Zhou, Hongfeng Qian
article en

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely used during pregnancy, but whether individual SSRIs differ in their developmental toxicity and long-term effects on offspring remains insufficiently understood. In this study, we comparatively evaluated prenatal exposure to sertraline, fluoxetine, and escitalopram in mice, with particular emphasis on maternal–fetal exposure, organ-specific developmental effects, and persistence of these alterations into adulthood. Pregnant mice received low or high doses of each SSRI from gestational day 0–18. Maternal and fetal biochemical profiles, fetal growth, organ morphology, and developmental markers were assessed, followed by evaluation of corresponding phenotypes in adult offspring. A high-fat diet (HFD) challenge was additionally applied to offspring prenatally exposed to low-dose sertraline to assess susceptibility to later-life metabolic stress. All three SSRIs crossed the placenta and altered maternal–fetal serotonergic homeostasis, but their developmental effects showed clear drug- and organ-specific patterns. The fetal brain exhibited relatively consistent susceptibility across exposure groups, whereas sertraline predominantly disrupted hepatic lipid metabolism and fluoxetine altered developmental markers in the kidney and gonads; escitalopram produced comparatively limited effects. Most fetal alterations in the brain, kidney, and gonads were not accompanied by detectable functional abnormalities at postnatal week 12. In contrast, sertraline-associated hepatic abnormalities, including increased FASN and CD36 expression and lipid accumulation, persisted into adulthood. Prenatal low-dose sertraline exposure also impaired glucose tolerance and insulin sensitivity and exacerbated HFD-induced hepatic lipid accumulation and metabolic injury. These findings demonstrate that developmental toxicity differs substantially among individual SSRIs despite their shared pharmacological class and highlight the importance of drug- and organ-specific evaluation in the long-term safety assessment of prenatal SSRI exposure.

Frontiers in PharmacologyVol. 17
Central South University (CN), Anhui Medical University (CN), Xiangya Hospital Central South University (CN), Huazhong University of Science and Technology (CN)
China Postdoctoral Science Foundation, Huazhong University of Science and Technology, Tongji University, Chinese Pharmaceutical Association, Science and Technology Program of Hunan Province
Good health and well-being
Prenatal Substance Exposure Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon